Multiple System Atrophy (MSA)
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BiohavenNEW HAVEN, CT
1 programBHV3241, verdiperstatN/ASmall Molecule1 trial
Active Trials
NCT05086094No Longer Available
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
Ono PharmaceuticalONO-2808
Clinical Trials (2)
Total enrollment: 92 patients across 2 trials
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Start: Sep 2023Est. completion: Jan 202792 patients
Phase 2Active Not Recruiting
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
N/ANo Longer Available
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.